Summary
Osteosarcoma is a rare, aggressive primary bone cancer that primarily affects adolescents and young adults. The total incident population across the seven major markets reached approximately 2,200 cases in 2025.
In the United States, Acrotech Biopharma’s Levoleucovorin (KHAPZORY) has received FDA approval, while in Europe, Esteve Pharmaceuticals’ Mifamurtide (MEPACT) is approved by the European Commission and authorized across the EU.
The development landscape is becoming increasingly diverse, with ADCs, immunotherapies, cancer vaccines, targeted inhibitors, radioligands, and cell-based therapies advancing through clinical development. Notable candi...